Sakaguchi’s main focus was on therapeutic immunity, either through adoptive tumor-primed CD4+ T-cells or by examining the ratio of CD8+ lymphocytes to tumor-infiltrating cells (34, 35). This evidence concerns the gene CD8A and neoplasm.